HomeLatest Pharma-NewsAZ's NDA filing anticipated based on positive data from interim analysis Latest Pharma-News AZ’s NDA filing anticipated based on positive data from interim analysis By admin June 22, 2022 0 50 Share FacebookTwitterWhatsAppLinkedin Share FacebookTwitterWhatsAppLinkedin Previous articleFDA Announces Plans for Proposed Rule to Reduce Addictiveness of Tobacco ProductsNext articleNovartis Tabrecta receives EC approval for METex14 skipping advanced nSCLC RELATED ARTICLES Latest Pharma-News J&J announced Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin admin - April 11, 2025 Latest Pharma-News Sanofi’s Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis admin - April 9, 2025 Latest Pharma-News Novartis receives FDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy admin - April 9, 2025 LEAVE A REPLY Cancel reply Comment: Please enter your comment! Name:* Please enter your name here Email:* You have entered an incorrect email address! Please enter your email address here Website: Save my name, email, and website in this browser for the next time I comment. Δ - Advertisment - Most Popular J&J announced Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin April 11, 2025 Sanofi’s Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis April 9, 2025 Novartis receives FDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy April 9, 2025 AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025 April 9, 2025 Load more